Day: May 9, 2024

AUBURN HILLS, Mich., May 09, 2024 (GLOBE NEWSWIRE) — SPAR Group, Inc. (NASDAQ: SGRP) (“SPAR”, “SPAR Group” or the “Company”), a leading global provider of merchandising and marketing services, today announces that it will release its 2024 fiscal first quarter results on Wednesday, May 15, 2024, before the market opens. In conjunction with the release, a conference call will be hosted by Mike Matacunas, Chief Executive Officer; and Antonio Calisto Pato, Chief Financial Officer, and will include a Q&A session following the prepared remarks starting at 10:00 am Eastern.By Phone: Dial 1-833-630-1542, or 1-412-317-1821 if calling from an International number, at least 10 minutes before the call and ask to be joined into the SPAR Group call. A replay will be available through May 22nd by dialing 1-877-344-7529 and using the conference...

ROUYN-NORANDA, Quebec, May 09, 2024 (GLOBE NEWSWIRE) — Abcourt Mines Inc. (“Abcourt” or the “Company”) (TSX Venture : ABI) is pleased to confirm a second gold mineralized zone East of the Flordin deposit toward the Cartwright deposit 100% owned by Abcourt. Highlights• A petrographic study confirms the presence of gold grains in the pyrite. These gold grains would be associated with the second phase of pyrite crystallization.• Compilation work has shown that the gold is not only contained in quartz veins and veinlets but also in sheared and altered zones, which are mineralized in disseminated pyrite.• The historical hole S-158 published in 1988 by Cambior Inc. intersected 3 g/t gold over 16 m in an altered, pyrite-mineralized zone without quartz veins (south zone).• The compilation work allows...

– FDA indicated IkT-001Pro can be considered a New Molecular Entity and is eligible for exclusivity designations in Pulmonary Arterial Hypertension – BOSTON and ATLANTA, May 09, 2024 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson’s disease, Parkinson’s-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that the Company has received final meeting minutes from its recent pre-IND meeting with the Division of Cardiology and Nephrology of the U.S. Food and Drug Administration (FDA) for IkT-001Pro (“Pro”) as a candidate treatment for Pulmonary Arterial Hypertension (PAH). Following review of the final meeting minutes,...

Earnings Results to be Released on Thursday, May 30, After the Close of the Market SAN JOSE, Calif., May 09, 2024 (GLOBE NEWSWIRE) — Zscaler, Inc. (NASDAQ: ZS), the leader in cloud security, will release third quarter fiscal year 2024 earnings after the market closes on Thursday, May 30, 2024. The company will host an investor conference call that day at 1:30 p.m. Pacific time (4:30 p.m. Eastern time) to discuss the results.Date: Thursday, May 30th, 2024Time: 1:30 p.m. PTWebcast: https://ir.zscaler.comDial-in: To join by phone, register at the following link: Click Here. After registering, you will be provided with a dial-in number and a personal PIN that you will need to join the call.Please dial in at least 10 minutes prior to the 1:30 p.m. PT start time. A live webcast of the conference call will be accessible...

Leveraging Akoya’s market-leading PhenoImager HT platform and clinical development expertise with NeraCare’s Immunoprint test and best-in-class clinical data, the partnership will focus on increasing access to life saving therapies for early-stage melanoma patients. MARLBOROUGH, Mass. and FRANKFURT, Germany, May 09, 2024 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company®, and NeraCare, a leading developer of laboratory tests for the prognosis of melanoma patients, announced an exclusive agreement today under which the parties will develop market opportunities for combining Akoya’s PhenoImager HT platform and NeraCare’s Immunoprint assay for patient stratification and therapy selection in early-stage melanoma patients. Melanoma is the leading cause of skin cancer-related deaths, with over 235,000...

SAN JOSE, Calif., May 09, 2024 (GLOBE NEWSWIRE) — Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present clinical and preclinical and data on the RaniPill® capsule, the company’s oral delivery platform, at Digestive Disease Week® (DDW) taking place both virtually and in-person on May 18-21, 2024 in Washington, DC. Details of the presentations are as follows: Abstract Title: An Orally Administered Robotic Pill (RP) Reliably and Safely Delivers an Ustekinumab Biosimilar RT-111 with High Bioavailability Relative to Subcutaneous (SC) Ustekinumab in Healthy Human ParticipantsSession Type: Late-Breaking Oral PresentationSession Title: IMIBD Late Breakers and Innovations in IBDSession...

Promoting Prestige Korean Beauty Products to Malaysia and Southeast Asia market NEW YORK and KUALA LUMPUR, Malaysia, May 09, 2024 (GLOBE NEWSWIRE) — Treasure Global Inc (NASDAQ: TGL) (“Treasure Global” or the “Company”), an innovative technology solutions provider, is thrilled to announce that its subsidiary, ZCITY, has secured a groundbreaking US$2 million marketing contract. This contract, honored by Satria Dunia Sdn Bhd, aims to promote prestige Korean beauty products through ZCITY’s advanced artificial intelligence marketing engine (“AI Marketing Engine”). This strategic move signifies a significant milestone for Treasure Global as ZCITY expands its presence and capabilities in the beauty industry. Leveraging ZCITY’s cutting-edge artificial intelligence technology, Treasure Global is poised to maximize brand visibility and...

BRISBANE, Calif., May 09, 2024 (GLOBE NEWSWIRE) — Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that Douglas Love, president and chief executive officer, will present at the Bank of America Health Care Conference on Tuesday, May 14, 2024 at 8:40 a.m. PT. A live webcast of the event can be accessed under the ‘Events & Presentations’ section on the Investors page at www.annexonbio.com. A replay of the webcast will be archived on the Annexon website for 30 days following the presentation. About Annexon Annexon Biosciences (Nasdaq: ANNX) is a biopharmaceutical company advancing a late-stage clinical platform of novel therapies...

SOMERSET, N.J., May 09, 2024 (GLOBE NEWSWIRE) — CareCloud, Inc. (the “Company” or “CareCloud”) (Nasdaq: CCLD, CCLDP and CCLDO), a leader in healthcare technology solutions for medical practices and health systems nationwide, today announced that it has retained Citizens JMP as its exclusive capital structure advisor. The retention of Citizens JMP by the Company was prompted by its recent receipt of an unsolicited indication of interest from a third-party to acquire the Company. The indication of interest proposed a meaningful premium to the common stock, together with treating the Company’s 11% Series A Cumulative Redeemable Perpetual Preferred Stock (“Series A Preferred Stock”) differently from the Company’s 8.75% Series B Cumulative Redeemable Perpetual Preferred Stock (“Series B Preferred Stock”), by virtue of their...